{"id":5470,"date":"2019-07-12T18:24:31","date_gmt":"2019-07-12T12:54:31","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=5470"},"modified":"2022-05-30T17:00:58","modified_gmt":"2022-05-30T11:30:58","slug":"idiopathic-pulmonary-fibrosis-scarring-for-a-lifetime","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/idiopathic-pulmonary-fibrosis-scarring-for-a-lifetime","title":{"rendered":"Idiopathic Pulmonary Fibrosis \u2013Scarring For A Lifetime"},"content":{"rendered":"\n<p>Sometimes, something gets missed from our eyes; often, our ignorance delays the diagnosis of something fatal.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/idiopathic-pulmonary-fibrosis-market\"><strong>Idiopathic Pulmonary fibrosis<\/strong> <\/a>is a chronic, rare, progressive fibrosing interstitial pneumonia. It is a harsh condition that scars the lung tissues for a lifetime and hampers the normal functioning of the lungs. It may hinder one&#8217;s breathing ability, which may ultimately lead to respiratory failure.<\/p>\n\n\n\n<p>The scarring begins at the edges of the lungs and advances\ntoward the centre. Though it may start mildly but eventually with time, it may\nworsen, and the lung tissue might get replaced with heavily scarred tissues\nthat will make it harder for a person to breathe properly and deliver the\nrequired amount of oxygen.<\/p>\n\n\n\n<p>Every year around 80,000 adults suffer from IPF in the United States, and more than 30,000 diagnosed IPF cases were observed.<\/p>\n\n\n\n<p>It often gets misdiagnosed as IPF symptoms are very similar\nto other lung diseases. Shortness of breath, particularly during exercise, dry,\nhacking cough, fast, shallow breathing, tiredness, aching joints, and muscles,\nand others are some of Idiopathic Pulmonary Fibrosis symptoms. The life\nexpectancy is about 2\u20135 years, with a mortality rate of about 50\u201356% after 5\nyears.<\/p>\n\n\n\n<p>Its severity differs from person to person, and every\nindividual diagnosed may have a different and unique experience. Some may\nbecome ill very quickly with severe disease. Others may have moderate symptoms\nthat worsen more slowly, over months or years. It leads to complications like\ncollapsed lung, lung infections, blood clots in the lungs, and lung cancer. <\/p>\n\n\n\n<p>A disease without any cure and any root cause have surprised many researchers and doctors as it does not showcase any severe symptoms till it has significantly damaged the organ. Therefore, current IPF treatment methods are dependant on antifibrotic drugs (Pirfenidone and Nintedanib). Innumerable tests have led to the production of new <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/idiopathic-pulmonary-fibrosis-market\">IPF <\/a><\/strong>therapies like Pemrevlumab, KD025, PRM151, GLPG 1690 and Thrombomodulin Alfa that are likely to launch in the coming years.<\/p>\n\n\n\n<p>Many companies are working robustly to identify IPF cause and targeted therapy to overcome the drawbacks of <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/idiopathic-pulmonary-fibrosis-epidemiology-forecast\">Idiopathic Pulmonary Fibrosis<\/a><\/strong> treatment. These therapies target a different mechanism and are expected to provide better Idiopathic Pulmonary Fibrosis treatment for patients.<\/p>\n\n\n\n<p>As per our recent analysis, the United States accounts for the largest <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/idiopathic-pulmonary-fibrosis-market-insight-epidemiology-and-market-forecast\">Idiopathic Pulmonary Fibrosis market<\/a><\/strong> size, in comparison to EU5 (United Kingdom, Spain, Italy, France, Spain) and Japan. The considerable growth will be observed at USD 4,861.2 Million in the forecasted years (2017-2028) in the US.<\/p>\n\n\n\n<p>To maintain a good quality of life and to keep oneself happy\nand healthy, one should eat right, reduce all the worries, stay active, and\nmanage the side effects of the given medications.<\/p>\n\n\n\n<p>Though this damage cannot be repaired, these medications\nwill ease the pain, and sometimes, a lung transplant may be fruitful for some.\nKnowing how long someone will live with IPF is difficult to determine. Every\nperson is different, and no one can be certain of what the individual\nexperience will be.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sometimes, something gets missed from our eyes; often, our ignorance delays the diagnosis of something fatal. Idiopathic Pulmonary fibrosis is a chronic, rare, progressive fibrosing interstitial pneumonia. It is a harsh condition that scars the lung tissues for a lifetime and hampers the normal functioning of the lungs. It may hinder one&#8217;s breathing ability, which [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":17499,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[651,5071,17738],"industry":[17225],"therapeutic_areas":[17243],"class_list":["post-5470","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-idiopathic-pulmonary-fibrosis","tag-idiopathic-pulmonary-fibrosis-market","tag-idiopathic-pulmonary-fibrosis-pipeline","industry-pharmaceutical","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Idiopathic Pulmonary Fibrosis \u2013Scarring For A Lifetime - DelveInsight<\/title>\n<meta name=\"description\" content=\"The considerable growth of Idiopathic Pulmonary Fibrosis will be observed at USD 4,861.2 Million in the forecasted years in the United States.....\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/idiopathic-pulmonary-fibrosis-scarring-for-a-lifetime\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Idiopathic Pulmonary Fibrosis \u2013Scarring For A Lifetime - DelveInsight\" \/>\n<meta property=\"og:description\" content=\"The considerable growth of Idiopathic Pulmonary Fibrosis will be observed at USD 4,861.2 Million in the forecasted years in the United States.....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/idiopathic-pulmonary-fibrosis-scarring-for-a-lifetime\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-07-12T12:54:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-05-30T11:30:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/07\/30170042\/idiopathic-pulmonary-fibrosis-scarring-for-a-lifetime.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Idiopathic Pulmonary Fibrosis \u2013Scarring For A Lifetime - DelveInsight","description":"The considerable growth of Idiopathic Pulmonary Fibrosis will be observed at USD 4,861.2 Million in the forecasted years in the United States.....","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/idiopathic-pulmonary-fibrosis-scarring-for-a-lifetime","og_locale":"en_US","og_type":"article","og_title":"Idiopathic Pulmonary Fibrosis \u2013Scarring For A Lifetime - DelveInsight","og_description":"The considerable growth of Idiopathic Pulmonary Fibrosis will be observed at USD 4,861.2 Million in the forecasted years in the United States.....","og_url":"https:\/\/www.delveinsight.com\/blog\/idiopathic-pulmonary-fibrosis-scarring-for-a-lifetime","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-07-12T12:54:31+00:00","article_modified_time":"2022-05-30T11:30:58+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/07\/30170042\/idiopathic-pulmonary-fibrosis-scarring-for-a-lifetime.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/idiopathic-pulmonary-fibrosis-scarring-for-a-lifetime","url":"https:\/\/www.delveinsight.com\/blog\/idiopathic-pulmonary-fibrosis-scarring-for-a-lifetime","name":"Idiopathic Pulmonary Fibrosis \u2013Scarring For A Lifetime - DelveInsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/idiopathic-pulmonary-fibrosis-scarring-for-a-lifetime#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/idiopathic-pulmonary-fibrosis-scarring-for-a-lifetime#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/07\/30170042\/idiopathic-pulmonary-fibrosis-scarring-for-a-lifetime.png","datePublished":"2019-07-12T12:54:31+00:00","dateModified":"2022-05-30T11:30:58+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The considerable growth of Idiopathic Pulmonary Fibrosis will be observed at USD 4,861.2 Million in the forecasted years in the United States.....","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/idiopathic-pulmonary-fibrosis-scarring-for-a-lifetime"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/idiopathic-pulmonary-fibrosis-scarring-for-a-lifetime#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/07\/30170042\/idiopathic-pulmonary-fibrosis-scarring-for-a-lifetime.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/07\/30170042\/idiopathic-pulmonary-fibrosis-scarring-for-a-lifetime.png","width":772,"height":482,"caption":"idiopathic-pulmonary-fibrosis-scarring-for-a-lifetime"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/07\/30170042\/idiopathic-pulmonary-fibrosis-scarring-for-a-lifetime-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Idiopathic Pulmonary Fibrosis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Idiopathic Pulmonary fibrosis market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Idiopathic Pulmonary Fibrosis Pipeline<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Idiopathic Pulmonary Fibrosis<\/span>","<span class=\"advgb-post-tax-term\">Idiopathic Pulmonary fibrosis market<\/span>","<span class=\"advgb-post-tax-term\">Idiopathic Pulmonary Fibrosis Pipeline<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 4 years ago"},"absolute_dates":{"created":"Posted on Jul 12, 2019","modified":"Updated on May 30, 2022"},"absolute_dates_time":{"created":"Posted on Jul 12, 2019 6:24 pm","modified":"Updated on May 30, 2022 5:00 pm"},"featured_img_caption":"idiopathic-pulmonary-fibrosis-scarring-for-a-lifetime","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5470","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=5470"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5470\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/17499"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=5470"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=5470"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=5470"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=5470"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=5470"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}